|Previous Section||Index||Home Page|
Mrs. Dunwoody: To ask the Secretary of State for Health how many NHS trust hospitals have rented (a) all and (b) part of their wards to pharmaceutical companies for experimental treatments in the last 12 months. 
Mrs. Dunwoody: To ask the Secretary of State for Health how many trust hospitals have taken part in Phase III trials of pharmaceuticals; which (a) hospitals and (b) pharmaceutical companies were involved; and what income was received by each trust. 
Mr. Ivan Lewis: For the period from September 2004 to September 2006, 260 United Kingdom hospitals have taken part in Phase III clinical trials of medicinal products. A table listing these hospitals has been placed in the Library. The number of pharmaceutical companies sponsoring Phase III clinical trials in the same time period is 215. These include companies based in the UK, other European Union member states and in non-European countries. A table listing these companies has been placed in the Library. Income accruing from the participation of trust hospitals in commercial clinical trials of medicinal products is not held centrally.
Mr. Ivan Lewis: National health service hospital trusts do not obtain commercial insurance cover for compensation claims incurred by private companies renting NHS wards. However, it is normal for the NHS to ask private companies in these circumstances to obtain their own indemnity cover.
Ms Rosie Winterton: All of the largest towns for each county in England, as defined by their urban population, have a general acute hospital locally with the exception of Rutland which has access to one close by in the neighbouring county.
The location of all health care services depends on many factors including population density, service need, value for money, geography and transport links. Any decisions on the location of health care services will be taken locally and will be reviewed over time to ensure they remain optimal.
Mr. Stephen O'Brien: To ask the Secretary of State for Health what the average cost was of health care procedures in (a) independent sector treatment centres and (b) on the NHS tariff in 2005-06. 
Mr. Ivan Lewis: The national tariff is a price indicator to be paid to national health service organisations for health care procedures and not a cost indicator. The national tariff is published on the Department's website at www.dh.gov.uk.
Across the full period of the wave one independent sector treatment centre (ISTC) contracts, the average percentage cost above the NHS equivalent cost of all wave one ISTCs is 11.2 per cent. and compares favourably with the historical cost of the NHS of spot purchasing from the independent sector.
Steve Webb: To ask the Secretary of State for Health how much her Department has spent on public health information campaigns on (a) sexual health and (b) safe alcohol consumption in each year from 1997 to 2005. 
|Sexual Health||Teenage Pregnancy||Alcohol( 1)|
|(1) There has been no major campaign expenditure on alcohol consumption in the financial years 1997-2005, so costs given relate to literature and website activity only. However the Department of Health and Home Office are developing a joint alcohol communications campaign for launch in October 2006. The Department is contributing £2 million to the cost of this campaign.|
Ms Rosie Winterton [holding answer 13 September 2006]: Following difficulties experienced in meeting the demand for home oxygen cylinders, especially standard and lightweight ambulatory cylinders, arrangements have now been made to make more cylinders available. The majority of patients in the two regions in the South East of England serviced by Allied Respiratory have transferred to the new supplier. Remaining patients are continuing to receive their oxygen cylinders through community pharmacies and are expected to transfer to Allied Respiratory over the next few weeks. Strategic health authorities and primary care trusts continue to monitor the situation and work with the supplier and clinicians to ensure patients needs are met.
Mr. Lansley: To ask the Secretary of State for Health how many hospital meals were left untouched in each year since 2001-02; and what this figure represents as a percentage of the total number of patient main meals in each year. 
|Untouched meals (Number)||Untouched meals (Percentage of total meals)|
plated meal systems: the number (calculated over the full menu cycle or seven days where no menu cycle is used) of untouched/unserved patient meals remaining at the end of the meals service period expressed as a percentage of the total number of meals provided and available at the commencement of the meal service period; and
bulk systems: an apportionment of remaining meals based on visual inspection expressed as percentage of the total number of meals able to be served.
A patient meal is defined as either a breakfast, midday or evening meal order (or any substitute or alternative for any such meals) received from a patient (wards and departments) or the number of similar meals provided to wards and departments as an estimate of need where order systems are not in use.
Mr. Ivan Lewis: The Department does not collect this information at present, and has no need to do so. All expenditure by the Department is conducted in accordance with the principles of the Treasury manual Government Accounting.
Mr. Lansley: To ask the Secretary of State for Health what recent representations she has received on supplies to the NHS of intravenous adrenaline; what the content of these representations was; which companies supply intravenous adrenaline to the NHS; and if she will make a statement on the supply of intravenous adrenaline to NHS organisations. 
Mr. Ivan Lewis: The Department and National Health Service Purchasing and Supply Agency are aware that there have been problems with the supply of adrenaline injection in pre-filled syringes, and have had representations from NHS pharmacists alerting them to the problem.
Adrenaline injection in pre-filled syringes is available from Cardinal Health and UCB Pharma Ltd., and in ampoules from Cardinal Health, Hameln Pharmaceuticals Ltd. and Goldshield Pharmaceuticals Ltd.
The shortage of adrenaline in pre-filled syringes arose due to a packaging problem with one of Cardinals other products, which had a knock-on effect. The problem has been resolved, and Cardinal say that stocks of adrenaline in pre-filled syringes will be fully replenished within the next two months. Adrenaline in pre-filled syringes is also available from UCB Pharma Ltd. There is no shortage of adrenaline injection in ampoules.
|Value (£ million)|
|(1) Forecast charges|
CSC also undertake IT infrastructure project work in support of the integrity, enhancement and resilience of the infrastructure in line with changing technologies. They also administer expenditure for IT services on behalf of the Department, for example British Telecom costs for the wide area network and business ports, and audio conferencing and mobile telephone costs. These project and pass-through costs are listed as follows.
|Value (£ million)|
|(1) Forecast charges|
2004-05: £5.6 million.
2004-05: A three year contract with three annual payments totalling £1.4 million.
2006-07: The value of this contract over the next five years is £6 million.
This annually renewable contract is for an application hosting provision designed to be scaleable to meet the requirements of the Department. The charges represent the fluctuation in these requirements. The annual charges were:
|Value (£ million)|
|Next Section||Index||Home Page|